🔗 Share this article

An underground market for unapproved slimming drugs is being driven by social media fitness personalities and vendors on messaging platforms, based on new investigations.

Investigational Treatment Gaining Traction Online

Retatrutide, which is still in clinical trials, is being advertised by social media influencers for its alleged weight-reducing effects. Followers are encouraged to contact these accounts privately for supplier links, while also receiving promotional offers.

Active Commerce on Messaging Platforms

Separately, a robust market exists on messaging services, where groups with numerous of members share “before and after” photos, injection guides and assertions of rapid UK delivery. Sellers promote the drug there before redirecting customers to other platforms for purchases.

Learning About The Experimental Drug

This medication is an experimental injectable developed by US drugmaker Eli Lilly. The treatment affects three intestinal hormones – glucagon-like peptide-1, GIP and pancreatic hormone. Early trials suggest it could help patients reduce up to a quarter of their body weight. Referred to as the “triple G”, the drug is being promoted online as the next Ozempic.

Healthcare Professionals Voice Concerns

Nevertheless, doctors and pharmacists have cautions that the distribution of what is still an unapproved medication in the UK is worrisome and could result in users administering products of uncertain source.

Several professionals stated the demand for retatrutide could be linked to the rising price of approved slimming treatments such as Mounjaro.

Regulatory Status and Implementation

Selling retatrutide on social media or Telegram is prohibited in the United Kingdom, as it is an unlicensed medication that cannot be promoted or supplied for human use under the Human Medicines Regulations 2012.

Some content creators try to sidestep the rules by referring to the drug as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a restricted substance, but advertising and supply can still breach medicines, marketing, and consumer regulations, potentially leading to penalties, prosecution or prison.

Platform Response and Content Elimination

According to the social media company, the platform has removed problematic material and banned associated hashtags and search suggestions. The organization stated it was committed to maintaining the platform safe and allocating resources in strengthening compliance measures.

Digital Trading Activities

Investigations also found groups with up to nine thousand members marketing the experimental drug using the platform's built-in discovery tool, which operates like a online catalog. Entering “retatrutide” immediately displays channels with thousands of members, populated with images of weight loss, positive reviews and detailed instructions for preparing or injecting at home.

Within moments of joining one group, a seller shared contact information, where most purchases occur. The seller sent an instruction manual and promised delivery within 48 hours. When asked whether the substance was genuine, one seller said: “You can’t be sure.” Another provided a image of a supposed testing documentation. None inquired about body mass, medical conditions or previous experience.

Product Information and Costs

Within these groups, messages show dark colored parcels with postal service labels, stating to include new batches. One communication stated: “It took eight of us to load them this morning.”

Customers can choose between powder vials, prepared at residence with sterile water, or pre-filled pens typically sold at £160 for 20mg. When questioned how much time a injector should be used, vendors give conflicting responses ranging from a few weeks to “depends on your body”.

Service Oversight and Security Measures

A representative for the messaging service said it actively monitored harmful material on its platform including material that promoted the “misuse of controlled medications”. The company noted that it removed “millions of pieces of harmful content each day”.

Medical Professional Warnings

“Individuals are administering substances they can’t verify. Although the science behind this drug is valid, these digital products may not include what they advertise,” stated a pharmacy expert, the head of pharmaceutical services at a pharmacy service.

Dr Crystal Wyllie of Asda Online Doctor linked the surge in demand to recent price rises for authorized slimming medications such as Mounjaro. “With costs rising, patients are turning to online platforms. But fake injections are highly risky. You can’t be certain what’s contained or whether the environment they were produced in was sterile,” she said.

Her staff has already encountered patients injured by self-injection from unconfirmed sources. “We recognize the disappointment, but buying from messaging apps or communication platforms is taking chances with your health,” said Wyllie. “These substances could be contaminated or incorrectly dosed.”

Producer Position

A representative from the pharmaceutical company said the substance was in third stage research studies and had not been evaluated or authorized by any regulatory agency globally. “Consequently at this point no one can market [it] for personal consumption,” they said, noting that any item “falsely representing itself as a Lilly investigational product not yet authorized … may expose users to potentially serious health risks”.